Post by Rinri Therapeutics

🧨 EU #Regenerative Medicine needs a 'trigger moment' of products with transformational patient impact, commercial viability & scalability, says Catenion research for the Novo Nordisk Foundation. Our #hearingloss otic neural progenitor cell therapy candidate, Rincell-1, will be part of this revolution, we believe. 🚀 Here's why it's one of the most transformative cell therapies in development: ☑️ Potential to stop & reverse debilitating and widespread neural hearing loss, with dramatic patient impact ☑️ Patient input embedded across development, contributing to a transformational target product profile ☑️ Disease-modification in an area of unmet medical need with a large population creates compelling commercial viability ☑️ Restoration of hearing loss complements the growing multimillion dollar longevity and healthspan market ☑️ Manufacturing process scalable to meet market demand at commercially viable COGs 🧏🏽 Hearing loss is the leading #sensory disability worldwide, with more than 7m people living with neural hearing loss. Current approaches such as cochlear implants have reached a performance plateau. Emerging therapies such as Rincell-1 are acutely needed, bringing natural hearing for patients and a trigger moment for the regenerative medicine sector. 👉🏽 Find out more about how hearing loss needn't be inevitable and why a cell therapy to treat it could be a healthspan blockbuster🔗 in comments ⤵️ #ATMP #SNHL

Video Content